D-0731-2026 Class II Ongoing
FDA drug recall D-0731-2026 was initiated by Glenmark Pharmaceuticals Inc., USA on Jul 23, 2026 and is designated Class II. Reason for recall: CGMP Deviations: Product quality complaints concerning abnormal texture or consistency (described as grainy, gritty, or sandy) were received. The recall status is ongoing.
Recall details
- Product Type
- Drugs
- Report Date
- Aug 5, 2026
- Initiation Date
- Jul 23, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
Azelaic Acid Gel, 15%, 50 gram tubes, For Topical Use only, Rx only, Distributed by: Glenmark Pharmaceuticals Inc., USA, Elmwood Park, NJ 07407, NDC 68462-626-52.
Reason for recall
CGMP Deviations: Product quality complaints concerning abnormal texture or consistency (described as grainy, gritty, or sandy) were received.
Distribution pattern
Nationwide within the United States.
Code information
Lot #: 19260937A, Exp. Date February 2028; 19261225A, 19261185A, Exp. Date March 2028; 19261664A, 19261682A, Exp. Date April 2028.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0731-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026